It takes a village has never been truer than when it comes to advancements in healthcare. Clinical trials are proven to be the best and most effective last steps in bringing new medical products to market.
One of UEL’s first residents, Prism Clinical Research they were a privately held investigatory site known for their focus on Phase I clinical trials in broad-based therapeutic populations. Their studies covered a wide-range of health concerns including HIV, renal problems, epilepsy and type 2 diabetes, many of which requires inpatient accommodations making bed space a large portion of their space at UEL.
Founded in 2005, Prism conducted more than 400 early-phase clinical trials supporting national and international pharmaceutical, biopharma, and medical device companies. 
These achievements gained the attention of Australia-based Nucleus Network, a 15+ year old company with their own proven and respected track-record in early phase clinical trials.
In 2019 Prism was acquired by Nucleus Network making them an international organization.
“Prism Clinical Research has a long and successful history of conducting complex early phase trials in patients and healthy volunteers in a safe and ethical manner. In particular, Prism Clinical Research are well known for their extensive expertise in conducting early phase hepatic and renally impaired clinical trials. This unique expertise is part of what makes Prism Clinical Research a very attractive business investment by Nucleus Network. We are excited about this important step for the broader Nucleus business and look forward to working with and welcoming the Prism team.” – Cameron Johnson, CEO Nucleus Network
Mentions & Memorable Milestones
- 2020 collaboration with University of Minnesota in COVID-19 prevention treatment study
- 2019 Prims Clinical Research is acquired by Nucleus Network
- 2019 TIMP- GLIA moves to Phase 2
- 2018 Successfully completes Phase 1 Study with TIMP- GLIA
- 2013 Prism Research receives Innovation and Excellence Award at the Innovation Forum
UEL is proud to have Nucleus Network in residence and look forward to seeing what healthcare contributions they continue to make here and worldwide.
Additional articles: Trial Site News Starting Up North
Link to learn more and/or contact Nucleus Network